UK's NICE Recommends Once-daily LIXIANA® (Edoxaban) for the Treatment and Prevention of Recurrent Deep Vein Thrombosis a

Forward-looking statements    

This press release contains forward-looking statements and information about future developments in the sector, and the legal and business conditions of DAIICHI SANKYO Co., Ltd. Such forward-looking statements are uncertain and are subject at all times to the risks of change, particularly to the usual risks faced by a global pharmaceutical company, including the impact of the prices for products and raw materials, medication safety, changes in exchange rates, government regulations, employee relations, taxes, political instability and terrorism as well as the results of independent demands and governmental inquiries that affect the affairs of the company. All forward-looking statements contained in this release hold true as of the date of publication. They do not represent any guarantee of future performance. Actual events and developments could differ materially from the forward-looking statements that are explicitly expressed or implied in these statements. DAIICHI SANKYO Co., Ltd. assume no responsibility for the updating of such forward-looking statements about future developments of the sector, legal and business conditions and the company.

References   

1) NICE. Edoxaban for treating and preventing deep vein thrombosis and pulmonary

embolism. Issued 26 August 2015. Available

at: http://www.nice.org.uk/guidance/TA354.  

2) NICE. Final appraisal determination: Edoxaban for preventing stroke and systemic

embolism in people with non-valvular atrial fibrillation. Issued 6 August 2015.

Available

at: https://www.nice.org.uk/guidance/gid-tag475/resources/atrial...

.  

3) Büller H et al. Edoxaban versus warfarin for the treatment of symptomatic venous

thromboembolism. New England Journal of Medicine. 2013; 369(15): 1406-1415.

4) Cohen AT et al. Venous thromboembolism (VTE) in Europe: the number of VTE events and

associated morbidity and mortality. Thrombosis and Haemostasis. 2007; 98(4): 756-764.

5) Kearon C. Natural history of venous thromboembolism. Circulation 2003;107(23 suppl 1)

:I-22-30.

6) NICE. Support for commissioning anticoagulant therapy. Commissioning guide 49. Issued

14 May 2013. Available at:

http://www.nice.org.uk/guidance/cmg49/resources/non-guidance...

. 

7) NICE. Venous thromboembolic diseases: the management of venous thromboembolic diseases

and the role of thrombophilia testing. NICE clinical guideline 144. Issued June 2012.

Contact 

Lydia Worms (Europe) 

Daiichi Sankyo Europe GmbH 

Edoxaban Comm. & Product PR Europe 

+49-(89)-7808751 

EmptyBreak:MARKER 

Yasuki Minobe (Global) 

Daiichi Sankyo Group 

Corporate Communications Department 

+81-(3)-62251126